13233-00-6

Usage

Uses

Used in Pharmaceutical Industry:
Isoquinoline, 3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-, hydrochloride is used as an intermediate in the synthesis of (-)-Higenamine (H325800) for the pharmaceutical industry. (-)-Higenamine is a naturally occurring alkaloid with potential applications in medicine, particularly as a bronchodilator and a muscle relaxant. The intermediate plays a crucial role in the production process, enabling the creation of the final pharmaceutical product.

Upstream product

• 4078-65-3 N-[2-(3,4-dimethoxy-phenyl)-ethyl]-2-(4-methoxy-phenyl)-acetamide 

Downstream Products

• 1213240-84-6 2-(5-fluoro-2-methoxyphenyl)-8,9-dimethoxy-1-(4-methoxyphenyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline 
• 1213240-81-3 5-(8,9-dimethoxy-1-(4-methoxyphenyl)-5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)-2-methoxyphenol 
• 1213240-76-6 4-(8,9-dimethoxy-1-(4-methoxyphenyl)-5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)phenol 
• 1213240-85-7 2-(5-fluoro-2-isopropoxyphenyl)-8,9-dimethoxy-1-(4-methoxyphenyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline 
• 72527-29-8 6,7-dimethoxy-1-(4-methoxybenzyl)-3,4-dihydroisoquinoline 

Relevant academic research and scientific papers

Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents

A new series of hybrids of lamellarin D and combretastatin A 4, 1,2-diphenyl-5,6-dihydropyrrolo [2,1-a] isoquinolines, were designed as cytotoxic agents based on principles of combination in medicinal chemistry and taking the parent compounds' different anti-proliferative mechanisms into consideration. Twenty-two novel hybrids were synthesized through a convenient route, with a key step of core pyrrole formation and evaluated for their anti-proliferative activities in vitro against K-562, A-549, SMMC-7721, SGC-7901 and HCT-116 cancer cell lines. The results showed that some hybrids had good anti-proliferative activities in low IC50 ranges.

NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS

The disclosure concerns novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions. The enantiomers of tetrahydroisoquinoline derivatives are provided which are useful in stimulating heart rate and hypotensive activity, inhibitory activity against platelet aggregation, and suppressive against inducible NO synthase. The enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts are effective for treating congestive heart failure, hypertension, thrombosis, inflammation, septicemia, cardiac insufficiency, and disseminated intravascular coagulopathy.